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Primary malignant ﬁbrous histiocytoma (MFH) of the lung is extremely rare although it is among the most common soft tissue
sarcomas in adults. Surgery is the primary mode of therapy, with high rates of local and distant recurrence, while radiation therapy
appears to be a very useful adjunct, decreasing local relapse. We report a case of primary malignant ﬁbrous histiocytoma of the
lung. Fourteen years after surgical resection, the patient is still alive although with multiple metastatic lesions throughout his body.
1.Introduction
Malignant ﬁbrous histiocytoma (MFH) occurs most com-
monly in the extremities (70–75%, with lower extremities
accounting for 59% of cases), followed by the retroperi-
toneum. Tumors typically arise in deep fascia or skeletal
muscle. MFH has been reported to occur in the lung,
kidney,bladder,scrotum,vasdeferens,heart,aorta,stomach,
small intestine, orbit, CNS, paraspinal area, dura mater,
facial sinuses, nasal cavity, oral cavity, nasopharynx, and soft
tissues of the neck. Although metastases to the lung are
common, primary lung malignant ﬁbrous histiocytoma is
extremely rare. We report a case of a 54-year-old male who
in 1995 was histologically diagnosed of having primary lung
MFH, reviewing the clinical and radiographic ﬁndings. He
had a 15-pack-year history of cigarette smoking but had not
smoked since 1986. The patient underwent surgical tumor
resection but didn’t receive any adjuvant therapy. Since
then multiple metastatic sites have developed but he is still
alive.
2.CaseReport
The patient was admitted to our hospital for the ﬁrst time
in 1986 when he underwent a chest X-ray, as part of routine
examination, which revealed a tumor shadow on left lung.
Physical examination revealed decreased breath sounds over
the left basal lung ﬁeld. Complete blood count, serum
biochemistry and tumor markers (including carcinoembry-
onic antigen, tissue plasmin antigen, and squamous cell
carcinoma antigen), were within normal limits. He denied to
undergo bronchoscopy and returned home. The patient was
readmittedtoourhospitalin25/4/1995suﬀeringfromsevere
cough, mucous expectoration and shortness of breath over
a three-month-period. Radiologic examinations included
chest chest X-rays and chest computerized tomography (CT)
scan. The spiral chest CT scan revealed a large tumor
of soft tissue density replacing most of the left lung and
occluding the lumen of the left main bronchus, associated
with atelectasis (Figure 1). A technetium-99m methylene
diphosphonate (ıTc-MDP) bone scan failed to show bone
metastases.
Under these circumstances, the patient was consented
for surgery and a left pneumonectomy was performed
(Figure 2). Histological studies of the mass revealed a
poorly diﬀerentiated mesenchymal neoplasm, consistent
with malignant ﬁbrous histiocytoma. In addition, an
immunohistochemical examination of the specimen showed
positive staining for CD68, α1-antichymotrypsin and factor
Xlla. No adjuvant chemotherapy or irradiation was given,
and the patient went home after 18 days of hospitalization
and follow up CT scans every six months.2 Case Reports in Medicine
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Figure 1: Tumor mass obstructing the left main bronchus.
L
Figure 2: Left pneumectomy; Nodular matastases.
Table 1
12/1995Chest CT
scan Few nodular densities in the right lung
04/1996Abdominal
CT scan
A metastasis to the right iliopsoas musle
Figure 3
11/1997Chest CT
scan
More nodules in the right lung with the
largest being approximately 3 cm.
04/2004- Brain
MRI Intraoccular mass on the left site Figure 4
In 1997, the patient presented a nodule on his left shoul-
der and underwent excision and biopsy. The histological
examination demonstrated tumor of mesenchymal origin
whichpresentedsimilarcharacteristicswiththeresectedlung
tumor.
In 2008, a chest CT scan showed innumerable, well
deﬁned of variable size hypodense nodules which presented
inhomogeneous contrast enhancement and scattered in the
right lung, the left postpneumonectomy space and the
mediastinum. It also revealed lesions of soft tissue density
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Figure 3: Metastatic lesion of the right iliopsoas muscle.
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Figure 4: Left intraocular mass.
in various parts of the thoracic wall, some of which were
associated with rib destruction (Figure 5). Furthermore, the
abdominal CT scan showed multiple circumscribed masses
occupying the retroperitoneal space, which displaced the
intestine anteriorly.
3. Discussion
MFH is the most common soft tissue sarcoma in adults,
comprising about 10% of all sarcomas, usually arising in the
extremities and trunk [1]. It may occur both in children and
infants [2]. It is an aggressive tumor with high potential of
local relapse and distant metastases. According to reportedCase Reports in Medicine 3
R
10cm
eﬀ.mAs 34
TI 0.8
GT 0.0
kV 130
Figure 5: Innumerable metastatic nodules with involvement of
thoracic wall.
studies lung is the most common site for distant metastases
[3].
We must take into consideration the fact that primary
MFH of the lung is extremely rare (0,2% of the pulmonary
neoplasms) with only about 50 cases been reported in the
literature [4] .T h e r em u s tb en oe v i d e n c eo fa n o t h e rp r i m a ry
site as determined by physical and radiologic exam before a
MFH can be considered a lung primary tumor. In our case,
no other primary site of disease was identiﬁed.
We must bear in mind that the majority of patients
present chest pain, dyspnea, cough, and hemoptysis. Less
common symptoms are hypertrophic pulmonary osteoar-
thropathy, hypoglycaemia, and neutrophilia. In addition,
patients may be asymptomatic during their presentation.
On the other hand, primary lung MFH of the lung
appears on CT as a peripheral tumor of soft tissue density
sometimes with areas of low attenuation centrally, bud
rarely cavitated. Despite the fact that has been found pleural
eﬀusion in 20% of patients calciﬁcation has been described
in only one adult patient in the literature [5]. Although
the radiologic manifestations have no diﬀerential points
from other lung tumors, chest CT to deﬁne of the size and
location of the tumor and the extent of the adjacent tissues
involvement.
Besides, the ﬁnal diagnosis is based on microscopic
and immunohistochemical studies [6], histologic typing is
based on Enzinger and Weiss classiﬁcation [7]( p l e o m o r p h /
storiform, myxoid, giant-cell, and inﬂammatory types).
Furthermore, the treatment of choice for primary lung MFH
is a complete surgical resection with negative microscopic
margins, associated to improved disease free speciﬁc survival
[8].Metastasesmayappearmonthsoryearsafterresectionof
the primary lesion.
Halyard et al. describe in their review eight patients with
primary lung MFH alive without evidence of disease more
than 5 years after the diagnosis (two of them for 10 years)
and one patient who died of the disease after a 6-year period.
Regnar et al. reported two patients who survived 11 years
after the operation [9]. Rzyman et al. reported one patient
alive with no evidence of disease 11 years postoperatively.
Moreover, survival after complete surgical resection in
cases of primary lung MFH has been reported to be better
than for other pulmonary sarcomas [4]. Many clinicopath-
ologic factors are signiﬁcally related to disease free speciﬁc
survival (DSS) and metastasis free survival (MFS), including
age, tumor size-depth, classiﬁcation stage, histologic type
and grade. As with other forms of soft tissue sarcomas
histopathologic grade is the most important factor deter-
minant in the characterization of disease stage [8]. In the
current case, most of these factors were associated with
adverse outcome, so we assume that the long patient’s
standing survival is related to a low grade primary tumor.
Last but not least, the role of adjuvant radiotherapy
and chemotherapy has not deﬁnitely been deﬁned yet.
Le Doussal et al. and Mills et al. clearly concluded that
radiotherapy signiﬁcantly reduces the risk of local relapse.
Edbronson et al reported no improvement after systematic
chemotherapy [10], but again Le Doussal et al. proposed
adjuvant chemotherapy in patients at increased risk for
distant metastasis.
4. Conclusion
To put it in a nutshell, we must take into account that
primary sarcomas of the lung are rare. Patients with MFH
of the lung must be carefully evaluated to rule out a
metastatic origin, as MFH is primarily a soft tissue tumor
of the extremities. Rates of local and distant recurrence
remain high even after radical surgery, but rare cases of
long-term survival have been reported. Histologic grade
seems to be the most important prognostic factor for
disease speciﬁc survival. Although the association between
metastases and cancer-related deaths is strongly signiﬁcant,
our patient has survived over 14 years developing multiple
metastases.
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